Is Troponin Elevation After TAVR Related to Mortality?

Troponins have long had diagnostic value not only for infarction. Their ability to predict mortality is well established for all cardiac conditions. Moreover, it has been demonstrated in all critically ill patients, including patients with COVID-19, regardless of the triggering condition.

¿La elevación de troponinas post TAVI tiene relación con la mortalidad?

While their significance in COVID cases is backed by the literature, there was not a robust publication addressing this phenomenon in relation with transcatheter aortic valve replacement (TAVR). This research investigated whether troponin elevation after TAVR is related to mortality, and it sought to determine a threshold.

The study included 1333 consecutive patients who underwent TAVR and had troponin values available.

A relevant injury after TAVR was defined as >18.3-fold increase of troponins compared with the baseline value. This association remained significant at 30 days and at 2 years, after adjusting for all confounding variables (hazard ratio [HR]: 1.90; 95% confidence interval [CI]: 1.40 to 2.57; p < 0001).


Read also: First Guidelines Focused Specifically on Chest Pain Management.


Certain subgroups also experienced mortality rates that were twice as high; examples included patients with coronary artery disease (HR: 2.17; p < 0.001), renal failure (HR: 2.17; p < 0.001), and intermediate or high surgical risk (HR: 2.70; p = 0.003).

Conclusion

This study determined that a 20-fold troponin elevation from the baseline value serves as a threshold for predicting mortality after transcatheter aortic valve replacement.

tropo-y-TAVI

Original Title: Postprocedural Troponin Elevation and Mortality After Transcatheter Aortic Valve Implantation.

Reference: Matthias Schindler et al. J Am Heart Assoc. 2021 Oct 29;e020739. Online ahead of print. doi: 10.1161/JAHA.120.020739.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...